Could fewer shots prevent rabies? new trial tests simpler vaccine schedules

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged between 10 and 60 years at the time of enrollment. * The participant and/or their legal guardian voluntarily agrees to participate in the trial and signs the informed consent form. * The participant and their family are able to comply with the trial follow-up schedule as required by the protocol (no plans for extended absence or relocation from the study site). * Female participants are neither pregnant nor lactating (negative urine pregnancy test prior to vaccination), and have no plans to become pregnant within 2 months after enrollment. Exclusion Criteria: a Exclusion criteria for the first dose: * Axillary body temperature ≥37.3°C at screening. * History of rabies vaccination or administration of rabies-specific passive immunization products, or history of bites/scratches by dogs or other mammals within the past year. * History of severe allergic reactions requiring medical intervention to any vaccine or vaccine components, such as anaphylactic shock, allergic laryngeal edema, allergic purpura, Arthus reaction, severe urticaria, or angioedema. * Fever, acute or chronic infectious diseases (e.g., active tuberculosis, viral hepatitis), or acute exacerbation of chronic illness within 3 days before the first vaccine dose. * Receipt of blood, blood products, or immunoglobulins within 3 months prior to the first vaccine dose, or planned use of such products within 1 month after the final vaccine dose. * Receipt of any other vaccines within 14 days prior to the first vaccine dose. * Asplenia or functional asplenia due to any condition (e.g., splenectomy). * Diagnosed congenital or acquired immunodeficiency (including HIV infection), or treatment with immunosuppressive agents within the past 3 months (e.g., systemic corticosteroids for ≥14 days at doses ≥2 mg/kg/day or ≥20 mg/day of prednisone or equivalent). * Presence of severe congenital malformations, autoimmune (hereditary) diseases, or severe chronic conditions (including but not limited to: thalassemia, heart disease, kidney disease, diabetes, hereditary allergic constitution, Guillain-Barré syndrome, etc.) * Personal or family history of convulsions, epilepsy, encephalopathy, or psychiatric disorders. * Contraindications to intramuscular injection (e.g., diagnosed thrombocytopenia, any coagulation disorder, or current use of anticoagulant therapy). * Uncontrolled hypertension (e.g., systolic BP ≥160 mmHg and/or diastolic BP ≥100 mmHg at screening for adults aged 18 years and above). * Currently participating in another clinical trial involving investigational or unregistered products (drugs or vaccines), or planning to participate in another clinical trial before completion of this study. * Any condition that, in the opinion of the investigator, may interfere with the evaluation of the study objectives. b Exclusion criteria for subsequent doses: * Positive urine pregnancy test； * Severe anaphylaxis after the previous dose; * Grade 4 adverse events associated with trial vaccination after the previous dose; * Exposure during the course (bite or scratch from dogs, cats or other mammals); * Participant has any other conditions that warrant discontinuation of vaccination as determined by the investigator.